CXCL14 and prostate adenocarcinoma: By performing consensus cluster analysis, PCa patients in TCGA-PRAD were divided into two clusters based on CXCL14, CCL20, CCL24, and CCL26 (Figures 2A–C), and compared to patients in cluster 1, PCa patients in cluster 2 had poor RFS (Figure 2D).